TRPX Therapix Biosciences Ltd.

$4.84 -2.42%

52,373 Shares Traded
246,751 Average Volume (last 30 days)

as of April 19, 2018 EST IEX Real-Time Price

Free Newsletter Sign Up

Short Pain Metrics

Approximate Amount of Money Shorts Have Made on the Day: $10.37 thousand
If Intiated on the First, Shorts Have Realized a Year to Date Return of:12.32%
If Intiated One Month Ago, Shorts Have Realized a Return of:14.18%
If Initiated Five Days ago, Shorts Have Realized a Return of:3.2%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points.

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingNeutral
200 Day Moving Average Indicator Bearish
50 Day Moving Average Indicator Bearish
52 Week High/Low Indicator Neutral

Short Stats

Short Percent to Float 2.47%
Short Interest86.39 thousand
Float3.5 million
Short Ratio5.33
Market Cap$16.93 million
Market Maker ActivityDaily Short Volume

News

04-10-2018
Your Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo Setback (SeekingAlpha)
04-09-2018
Midday Gainers / Losers (04/09/2018) (SeekingAlpha)
04-09-2018
Premarket Gainers as of 9:05 am (04/09/2018) (SeekingAlpha)
04-09-2018
Therapix Biosciences announces results of Phase IIa study at for Tourette syndrome program; shares ahead 35% premarket (SeekingAlpha)
04-09-2018
Therapix Biosciences Announces Topline Results of Phase IIa Study at Yale University for Tourette Syndrome Program (PR Newswire)
03-21-2018
Your Daily Pharma Scoop: Arena Soars, Roche Data, GlaxoSmithKline Commences Study (SeekingAlpha)
03-20-2018
Premarket Gainers as of 9:05 am (03/20/2018) (SeekingAlpha)
03-20-2018
Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain (PR Newswire)
02-07-2018
Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected (PR Newswire)
01-09-2018
Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update Today at the Biotech Showcase(TM) 2018 (PR Newswire)


Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 0.3%

Earnings Stats

PE Ratio
Dividend Yield 0%
Peer EarningsEarnings Calendar

Technicals

200 Day Moving Average $5.67
50 Day Moving Average $5.48
52 Week High $7.8
52 Week Low $4.26



Data provided for free by IEX. Questions? Read the FAQ